The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Understanding SLE-Associated Skin Injury May Open the Door to Therapies

Understanding SLE-Associated Skin Injury May Open the Door to Therapies

September 7, 2015 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR_SystemicLupusErythematosus500x500As with many conditions, systemic lupus erythematosus (SLE) is influenced by both genetic and environmental factors. Not surprisingly, in the case of SLE, genetic risk factors tend to be associated with the immune system. Environmental risk factors that influence the clinical presentation of SLE include exposure to ultraviolet (UV) rays and smoking. Both of these exposures are associated with skin injury and may even induce systemic inflammation in patients with SLE. Patients with SLE are often hypersensitive to sunlight and may experience skin inflammation. In addition, smoking worsens the severity of cutaneous lupus erythematosus (CLE).

You Might Also Like
  • ACR/ARHP Annual Meeting 2012: Understanding Pain Signals May Pave Path to More Effective Therapies
  • Effectiveness of Novel Therapies for Cutaneous SLE Explored
  • FOCIS 2015: Research Increases Understanding of Lupus, RA
Also By This Author
  • Gene Signatures in IgG4-Related Disease

Despite these intriguing observations, the pathogenesis of skin injury in patients with SLE has yet to be elucidated. Guo-Min Deng, MD, PhD, director of the Department of Microbiology and Immunology, Nanjing Medical University in China, and George C. Tsokos, MD, professor of Medicine at Harvard Medical School in Boston, reviewed the topic online on Aug. 4 in Nature Reviews Rheumatology. They described how exposure to UV light appears to cause the release of autoantigens and the local production of inflammatory cytokines.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Patients with SLE have high titers of autoantibodies that may deposit as immune complexes associated with organ damage. Patients with SLE and skin lesions have autoantibodies against 60S acidic ribosomal protein P0 (RPLP0) and galectin 3. They also tend to have immune complexes of IgG, IgM and complement component 3 (C3) deposited in their dermoepidermal junctions. The deposits can actually be seen in skin biopsy specimens of both SLE patients with skin lesions and those without lesions. The difference between the two groups is that patients with skin lesions have inflammatory cell infiltrations in addition to the immune complex deposits. Moreover, the proinflammatory cytokine tumor necrosis factor (TNF) is over expressed in the kidneys and skin lesions of individuals with SLE. Thus, skin lesions appear to require the same pattern of immune cell response as the systemic manifestations of SLE.

Investigators have also been able to study the process of skin injury in the MRL/lpr mouse model for SLE. These mice develop lupus nephritis, but only in the presence of interferon (IFN)-ɣ and IFN-ɣ receptor (CD119). After exposure to UV light, the keratinocytes in the mice produce macrophage colony-stimulating factor 1 (CSF-1), which recruits and activates monocytes. In addition, studies with the mice have revealed that intradermal injection of lupus serum IgG results in skin inflammation.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Deng and Dr. Tsokos explain that, “Our research suggests that IgG has a key role in the development of lupus-related skin inflammation. Injection of lupus sera—from either lupus-prone mice or patients with SLE—into the dermis of wild-type C57Bl/6 mice resulted in an intense, but self-limited, inflammatory response, which was not observed after the injection of normal serum, buffered saline or IgG-depleted sera.” The authors concluded that UV light activates immune cells in areas where IgG has been deposited.

Pages: 1 2 | Single Page

Filed Under: Conditions, SLE (Lupus) Tagged With: Lupus nephritis, skin, skin inflammation, systemic lupus erythematosus (SLE), ultraviolet light

You Might Also Like:
  • ACR/ARHP Annual Meeting 2012: Understanding Pain Signals May Pave Path to More Effective Therapies
  • Effectiveness of Novel Therapies for Cutaneous SLE Explored
  • FOCIS 2015: Research Increases Understanding of Lupus, RA
  • Anti-TNF-Associated Skin Lesions Common in Inflammatory Bowel Disease

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)